The clinical features and treatments of 11 RA patients with OIIA CD4+ T-LPDs (52%), 9 with CD8+ T-LPDs (43%), and 1 with CD4− CD8− TNK-LPDs (5%) are shown in Tables 1 and 2. This evidence concerns the gene CD4 and rheumatoid arthritis.